Urapidil


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO HTN 30-90 mg twice daily. IV Hypertensive crisis Initial: 25 mg, repeat after 5 mins if needed. May repeat w/ another 50 mg dose 5 mins later if still needed. Maintenance: 9-30 mg/hr once BP is reduced sufficiently.
Dosage Details
Intravenous
Hypertensive crisis
Adult: Initially, 25 mg by slow inj over 20 seconds, repeat if necessary after 5 minutes. This may be followed by 50 mg after another 5 minutes if response is insufficient. Continue with a maintenance infusion of 9-30 mg/hr once BP is reduced sufficiently.

Oral
Hypertension
Adult: 30-90 mg bid.
Hepatic Impairment
Severe: Use with caution.
Contraindications
Aortic stenosis (IV), lactation.
Special Precautions
Elderly, severe hepatic insufficiency. Pregnancy.
Adverse Reactions
Dizziness, nausea, headache, fatigue, orthostatic hypotension, palpitations, nervousness, pruritus and allergic skin reactions.
Drug Interactions
Increased risk of hypotension with other antihypertensives. Decreased antihypertensive effect with NSAIDs.
Action
Description: Urapidil is a centrally acting antihypertensive that blocks peripheral α1-adrenoceptors. It reduces peripheral resistance which leads to a fall in systolic and diastolic BP, without reflex tachycardia.
Pharmacokinetics:
Absorption: Rapidly absorbed. Bioavailability: 70-80%.
Distribution: Protein binding: 80%
Metabolism: Extensively metabolised in liver, mainly by hydroxylation. Elimination half-life: 4.7 hr (oral) and 2.7 hr (IV).
Excretion: Excreted in urine as metabolites and unchanged drug (10-20%)
Disclaimer: This information is independently developed by MIMS based on Urapidil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in